Changeflow GovPing Healthcare & Life Sciences CRISPR Enzymes and Systems
Routine Notice Added Draft

CRISPR Enzymes and Systems

Favicon for changeflow.com USPTO Patent Applications - Biotech (C12N)
Published
Detected
Email

Summary

The USPTO published patent application US20260092266A1 by Feng Zhang et al. for engineered CRISPR-Cas systems comprising multimeric complexes with β-CASP polypeptides and small Type II-B, II-C, and II-D Cas proteins for modifying target polynucleotides. The application (No. 19388533) was filed November 13, 2025, and published April 2, 2026.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

The USPTO published a patent application for engineered CRISPR-Cas gene editing systems developed by Feng Zhang, Han Altae-Tran, and Soumya Kannan. The application covers multimeric CRISPR-Cas complexes containing β-CASP polypeptides, multiple Cas polypeptides, and guide molecules, as well as small Cas proteins from Type II-B, II-C, and II-D categories, including packaging and delivery systems and methods for modifying target polynucleotides.

This is a standard patent publication providing public notice of a biotechnology invention. No compliance actions are required from other entities. Companies developing gene therapies or CRISPR-based applications should review the published claims to assess potential IP overlap with their own research programs.

Archived snapshot

Apr 2, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

CRISPR ENZYMES AND SYSTEMS

Application US20260092266A1 Kind: A1 Apr 02, 2026

Inventors

Feng Zhang, Han Altae-Tran, Soumya Kannan

Abstract

Described herein are engineered, non-naturally occurring systems and compositions comprising multimeric CRISPR-Cas complexes comprising a β-CASP polypeptide, a plurality of Cas polypeptides, and a guide molecule, packaging and delivery systems thereof, and methods of use thereof, for modifying target polynucleotides. In addition, described herein are engineered, non-naturally occurring systems and compositions comprising a class of small Cas proteins (Type II-B, II-C, and II-D Cas proteins) and methods of modifying target sequences using the Type II-B, II-C, II-D Cas proteins and systems thereof.

CPC Classifications

C12N 9/222 C12N 15/111 C12N 15/8203 C12N 15/86 C12N 15/902 C07K 2319/09 C12N 2310/20

Filing Date

2025-11-13

Application No.

19388533

View original document →

Named provisions

Abstract Inventors

Get daily alerts for USPTO Patent Applications - Biotech (C12N)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 2nd, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Draft
Change scope
Minor
Document ID
US20260092266A1
Docket
19388533

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254.1 Biotechnology 3254 Pharmaceutical Manufacturing
Activity scope
Patent Applications
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Biotechnology Healthcare

Get alerts for this source

We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!